TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06032546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous (IV) Infusion
Study: NCT04808284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct-current stimulation
Description: A single tDCS session will be delivered to the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be used, with one electrode (anode) placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region, according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct-current stimulation
Description: A single tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed over F3 (anode) and F4 (cathode), according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
Study: NCT05324943

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FLT201
Description: FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
Study: NCT05209243

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT (all metastatic lesions)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD OF CARE
Description: ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: STANDARD OF CARE
Description: ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
Study: NCT05164276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head position
Description: Before nasotracheal intubation, patient's head is positioned to one of three positions according to assigned group: sniffing, neutral or flexed position.
Study: NCT04808284

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct-current stimulation
Description: A single Sham-tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) or over the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). A pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed according to the International 10-20 EEG system. For SMA , one electrode (anode) will be placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region. For DLPFC, electrodes will be placed over F3 (anode) and F4 (cathode). Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 seconds current intensity will be ramp down for 15 seconds.
Study: NCT06086691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training with Caffeine
Description: The intervention protocol consists of 5 types of strength training exercises. The following exercises will be performed for the strength training group:~1. bench press (3 sets of 10 reps)~2. biceps curl (3 sets of 10 reps)~3. triceps pushdown (3 sets of 10 reps)~4. leg press (3 sets of 10 reps)~5. leg extension (3 sets of 10 reps)~Strength training would be performed in 3 sets of 10 repetitions with 2 minutes of rest between each exercise. This protocol will be performed in a 30-40-minute session. 10-15 minutes of light warm-up activities will be performed before the start of each exercise session. The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training with Caffeine
Description: The intervention protocol consists of 3 types of endurance training exercises. The following exercises will be performed by this group:~1. Cycling (15 min)~2. Running (20 min)~3. Rowing (10 min)~The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions.
Study: NCT04432337

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The role of the activation of the NLRP3 inflammasome after cardiac surgery
Description: Determine the effect on the inflammatory response post extracorporeal circulation mediated by the NLRP3 inflammasome, in patients after cardiac surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The role of the activation of the NLRP3 inflammasome after cardiac surgery
Description: Determine the effect on the inflammatory response post extracorporeal circulation mediated by the NLRP3 inflammasome, in patients after cardiac surgery
Study: NCT05559879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabo + Dostarlimab
Description: Combination of standard dose of cabozantinib and 500 mg dostarlimab for first 4 cycles followed by standard dose of cabozantinib and 1000 mg of dostarlimab until 2 years of treatment
Study: NCT05946265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: 120 patients with dentin sensibility after non-surgical scaling and root planning (SRP) will be randomly included in 2 groups: Experimental Group: SRP+ Photobiomodulation (PBM) The dosimetric parameters for the treatment included a wavelength of 660 nm applied in continuous mode with a radiant power of 100 mW (0.1 W). The irradiance ranged from 35.385 mW/cm² to 35 W/cm², with a beam area of 0.002826 cm². Each point received an exposure time of 30 seconds, resulting in a radiant exposure of 1.061 J/cm² and a total radiant energy of 3 J. The procedure involved six irradiated points per tooth, distributed across the vestibular surface (apical, middle, and cervical regions) and the palatal surface. The application technique was performed in contact, maintaining a 90-degree angle to the surface. The treatment consisted of a single session.
Study: NCT06032546

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: IV Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-382
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-382
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Subcutaneous (SC) Injection
Study: NCT06630234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3009
Description: Administered orally
Study: NCT04712097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)
Study: NCT04303208

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: Blood sample ( 5 ml venous blood ) will be obtained under complete aseptic conditions from all eligible participants , using serum separator tube and allow samples to clot for 30 minutes before centrifugation for 15 minutes to obtain clear serum . Separated serum will be stored at \< - 20c ( avoid repeated freeze - thaw cycles ) till assessment of Sirt 3 and Sirt 7 levels using Enzyme- linked immunosorbent assay (ELISA) method .
Study: NCT04712097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11
Study: NCT05562037

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stepped Care
Description: Patients meeting a non-response criterion will be stepped up to the next step
Study: NCT04712097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tociluzumab
Description: Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tociluzumab
Description: Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tociluzumab
Description: Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events
Study: NCT06351345

Intervention type: DRUG
Group type: OTHER
Intervention: 129Xe Hyperpolarized
Description: Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).
Study: NCT06545916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunobinop
Description: 1 tablet taken orally at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match sunobinop
Description: 1 tablet taken orally at bedtime
Study: NCT05164276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head position
Description: Before nasotracheal intubation, patient's head is positioned to one of three positions according to assigned group: sniffing, neutral or flexed position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head position
Description: Before nasotracheal intubation, patient's head is positioned to one of three positions according to assigned group: sniffing, neutral or flexed position.
Study: NCT04899310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-3705
Description: A sterile liquid for injection
Study: NCT06529770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP-e
Description: The US-PNM intervention uses a square-wave biphasic current (10 Hz, 250 ms pulse width) at maximum tolerable intensity for 1.5 minutes (10 seconds 10 times), per Fermín Valera and Fran Minaya's protocol. Participants will lie on their side, with the area cleaned and an ultrasound probe cover used.~Needles (Agu Punt, Spain) will be inserted perpendicularly to target the nerve perineurium. For the axillary nerve (C5-C6), a 0.40/0.50×25 mm needle will be used in a short axis at 80°. For the suprascapular nerve (C5-C6), a 0.30/0.40×25 mm needle will be used.~Each session involves two needle insertions, with the needle stationary and monitored by a physiotherapist with two years of experience.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP-e
Description: The US-PNM intervention uses a square-wave biphasic current (10 Hz, 250 ms pulse width) at maximum tolerable intensity for 1.5 minutes (10 seconds 10 times), per Fermín Valera and Fran Minaya's protocol. Participants will lie on their side, with the area cleaned and an ultrasound probe cover used.~Needles (Agu Punt, Spain) will be inserted perpendicularly to target the nerve perineurium. For the axillary nerve (C5-C6), a 0.40/0.50×25 mm needle will be used in a short axis at 80°. For the suprascapular nerve (C5-C6), a 0.30/0.40×25 mm needle will be used.~Each session involves two needle insertions, with the needle stationary and monitored by a physiotherapist with two years of experience.
Study: NCT06224348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: injection solution Route of administration: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Description: Pharmaceutical form: Topical formulation Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Description: Pharmaceutical form: Topical formulation Route of administration: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical corticosteroids
Description: Pharmaceutical form: Topical formulation Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical calcineurin inhibitors
Description: Pharmaceutical form: Topical formulation Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical calcineurin inhibitors
Description: Pharmaceutical form: Topical formulation Route of administration: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical calcineurin inhibitors
Description: Pharmaceutical form: Topical formulation Route of administration: Topical
Study: NCT06034028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Valve TF System
Description: The J-Valve TF System is a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis, J-Valve TF Delivery Device, and Loading Accessories.
Study: NCT05856552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive behavioral therapy delivered by community resource persons via home visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive behavioral therapy delivered by community resource persons via home visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Activities
Description: Weekly hour-long group activities delivered by community resource persons in community spaces.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Activities
Description: Weekly hour-long group activities delivered by community resource persons in community spaces.
Study: NCT06097650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold snare polypectomy
Description: Histological analyses suggest that cold snare polypectomy causes less damage to blood vessels in the submucosal layers, which results in a reduced incidence of hemorrhage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hot snare polypectomy
Description: Current guidelines recommend preoperative hot snare polypectomy after preoperative saline injection, nylon ring, or metal clip ligation of the tip and pedicle of the polyps
Study: NCT06213311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axi-cel
Description: Given by IV
Study: NCT05795842

Intervention type: DEVICE
Intervention: wearable wristband model
Description: MOTO 360 smartwatch: is a specific consumer wearable wristband model (Motorola: MOTO 360), fitted with proprietary firmware (LifeQ) to collect continuous biometric signals, including PPG signals and 3-axis accelerometers in an ambulatory setting. The device is not a medical or diagnostic device, but rather a photoplethysmography (PPG) data collection device. PPG is a non-invasive technology that uses light to measure the change in the volume of blood beneath the skin that occurs as the heart beats. LifeQ has developed software that enables the collection of vital signs data from PPG technology.

Intervention type: OTHER
Intervention: Samsung Galaxy Watch 6
Description: The Samsung Galaxy Watch6 will collect study data on physiological signals with a compatible Samsung Galaxy phone S21. The Samsung Galaxy Watch6 will include various models, the difference being the size of the watch face or the analog front end of the device.~The software device is installed on the Samsung Galaxy Watch. The app on the watch continuously records PPG and/or ECG data and transmits it. The phone app allows study staff to enter the subject ID, initiate data collection, and stop data collection sessions on the watch. It also receives and stores PPG and ECG data from the paired watch. The PPG app used in the study does not trigger irregular rhythm notifications or display rhythm classification. The data collected using the PPG app will support algorithm development.

Intervention type: DEVICE
Intervention: Standard of care extended ECG monitoring
Description: Participants enrolled in the study are prescribed ambulatory ECG monitoring (Mobile Cardiac Outpatient Telemetry, Biotel e-Patch, or LINQ insertable cardiac monitor). If the patient is negative for Afib during their time wearing an ECG monitoring patch, then patients may proceed with LINQ insertable cardiac monitor, as part of their standard of care. These are standard-of-care FDA-approved devices and detection software. Researchers will rely on the final ECG report to identify arrhythmic events to use as a golden standard to evaluate the algorithm findings. Specifically, the raw data will be used for establishing and getting an accurate ground truth for the algorithm.
Study: NCT05832580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etidronate
Description: Etidronate in capsules of 200 mg or 400 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in similar capsules
Study: NCT06373497

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18-F-NaF Cardiac PET/MRI and
Description: All eligible subjects will receive 18-F-NaF Cardiac PET/MRI at baseline and 6 months after the completion of radiotherapy where the heart is in the treatment field

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Angiogram
Description: All eligible subjects will receive CT Angiogram at baselin
Study: NCT06407934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution~Route of administration: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution~Route of administration: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution~Route of administration: SC injection
Study: NCT06350084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother's Touch
Description: Heel blood will be taken while the infant was Mother's Touch. Mother's touch will be applied to the infants before, during and after the procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse's Therapeutic Touch
Description: Heel blood will be taken while the infant was Nurse's Therapeutic Touch.Therapeutic Touch will be applied to the infants before, during and after the procedure.
Study: NCT06646627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B7-H3CART
Description: Dose Levels:~Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3~Arm A IP(± 20%) (flat dose) Dose Level -1: 1 x 107 B7-H3CART Dose Level 1: 5 x 107 B7-H3CART Dose Level 2: 15 x 107 B7-H3CART Dose Level 3: 5 x 108 B7-H3CART~Arm B: IV (± 20%) (weight based) Dose Level -1: 3 x 105 transduced cells/kg Dose Level 1: 1 x 106 transduced cells/kg Dose Level 2: 3 x 106 transduced cells/kg Dose Level 3: 10 x 106 transduced cells/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B7-H3CART
Description: Dose Levels:~Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3~Arm A IP(± 20%) (flat dose) Dose Level -1: 1 x 107 B7-H3CART Dose Level 1: 5 x 107 B7-H3CART Dose Level 2: 15 x 107 B7-H3CART Dose Level 3: 5 x 108 B7-H3CART~Arm B: IV (± 20%) (weight based) Dose Level -1: 3 x 105 transduced cells/kg Dose Level 1: 1 x 106 transduced cells/kg Dose Level 2: 3 x 106 transduced cells/kg Dose Level 3: 10 x 106 transduced cells/kg
Study: NCT05652699

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Oxygen
Description: Flow 60L/minute. FiO2 according to clinical protocol. Temperature highest tolerated by patient, starting with 37 degrees Celsius.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oxygen Therapy
Description: Nasal Cannula, Venturi Mask or Non-rebreathing mask, according to local clinical protocols
Study: NCT05240976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE plus AIFA
Description: Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NMDAE plus Placebo Cap
Description: Use of an NMDA enhancer plus placebo as a comparator
Study: NCT05725187

Intervention type: DEVICE
Intervention: MobiCare
Description: It is a 9.2g wearable electrocardiogram device, mobiCARE, in the form of a patch, and the model name is MC200M.

Intervention type: DEVICE
Intervention: MobiCare
Description: It is a 9.2g wearable electrocardiogram device, mobiCARE, in the form of a patch, and the model name is MC200M.
Study: NCT06348719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopy
Description: The experimental procedure corresponds to robot-assisted laparoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopy
Description: The control procedure corresponds to conventional laparoscopy.